CONNECT BIOPHARMA HOLDINGS L

Connect Biopharma’s Phase‑2 asthma data shows a 66% reduction in treatment failure and rapid lung‑function gains, sparking investor debate and a fresh outlook for its IL‑4Rα drug.

Connect Biopharma’s Q1‑Q2 2026 results show rising licensing revenue and Phase 2 R&D spending for rademikibart, hinting at future growth despite current losses.